These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26083005)

  • 1. Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases.
    Narayana A; Manoharan A; Narayan MS; Kalappa SM; Biligumba G; Haradanahalli R; Anand AM
    Hum Vaccin Immunother; 2015; 11(7):1748-53. PubMed ID: 26083005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab).
    Ashwathnarayana DH; Madhusudana SN; Sampath G; Sathpathy DM; Mankeshwar R; Ravish HH; Ullas PT; Behra TR; Sudarshan MK; Gangaboraiah ; Shamanna M
    Vaccine; 2009 Dec; 28(1):148-51. PubMed ID: 19818720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
    Kerdpanich P; Chanthavanich P; De Los Reyes MR; Lim J; Yu D; Ama MC; Mojares Z; Casula D; Arora AK; Pellegrini M
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006340. PubMed ID: 29874228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis.
    Ravish HS; Vijayashankar V; Madhusudana SN; Sudarshan MK; Narayana DH; Andanaiah G; Ashwin BY; Rachana AR; Shamanna M
    Hum Vaccin Immunother; 2014; 10(8):2433-7. PubMed ID: 25424951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India.
    Sudarshan MK; Narayana DH; Madhusudana SN; Holla R; Ashwin BY; Gangaboraiah B; Ravish HS
    Hum Vaccin Immunother; 2012 Aug; 8(8):1077-81. PubMed ID: 22699446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.
    Ma J; Wang H; Li J; Chang L; Xie Y; Liu Z; Zhao Y; Malerczyk C
    Hum Vaccin Immunother; 2014; 10(10):2805-12. PubMed ID: 25483635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.
    Li R; Huang L; Li J; Mo Z; He B; Wang Y; Wu X; Minutello M; Guinet-Morlot F; Pichon S
    Vaccine; 2013 Dec; 31(50):5940-7. PubMed ID: 24148575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.
    Quiambao BP; Ambas C; Diego S; Bosch Castells V; Korejwo J; Petit C; Houillon G
    Vaccine; 2019 Apr; 37(16):2268-2277. PubMed ID: 30890382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India.
    Ashwath Narayana DH; Madhusudana SN; Sampath G; Tripathy RM; Sudarshan MK; Gangaboraiah ; Ravish HS; Satapathy DM; Gowda G; Holla R; Ashwin BY; Padhi A; Manjula S; Patel PM
    Hum Vaccin Immunother; 2014; 10(1):120-5. PubMed ID: 24030586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.
    Li R; Li Y; Wen S; Wen H; Nong Y; Mo Z; Xie F; Pellegrini M
    Hum Vaccin Immunother; 2015; 11(2):435-42. PubMed ID: 25692350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen).
    Mahendra BJ; Narayana DA; Agarkhedkar S; Ravish HS; Harish BR; Agarkhedkar S; Madhusudana SN; Belludi A; Ahmed K; Jonnalagedda R; Vakil H; Bhusal C; Arora AK
    Hum Vaccin Immunother; 2015; 11(2):428-34. PubMed ID: 25692792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
    Quiambao BP; Ambas C; Diego S; Bosch Castells V; Korejwo J; Petit C; Rasuli A; Houillon G
    Vaccine; 2020 May; 38(21):3740-3746. PubMed ID: 32280042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postexposure rabies prophylaxis completed in 1 week: preliminary study.
    Shantavasinkul P; Tantawichien T; Wilde H; Sawangvaree A; Kumchat A; Ruksaket N; Lohsoonthorn V; Khawplod P; Tantawichien T
    Clin Infect Dis; 2010 Jan; 50(1):56-60. PubMed ID: 19995217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
    Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
    Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial.
    Pichon S; Guinet-Morlot F; Minutello M; Donazzolo Y; Rouzier R; Chassard D; Fitoussi S; Hou V
    Vaccine; 2013 Apr; 31(18):2295-301. PubMed ID: 23510665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economical multi-site intradermal regimen with purified chick embryo cell vaccine (Rabipur) prevents rabies in people bitten by confirmed rabid animals.
    Madhusudana SN; Anand NP; Shamsundar R
    Int J Infect Dis; 2002 Sep; 6(3):210-4. PubMed ID: 12718837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe.
    Kamoltham T; Thinyounyong W; Phongchamnaphai P; Phraisuwan P; Khawplod P; Banzhoff A; Malerczyk C
    J Pediatr; 2007 Aug; 151(2):173-7. PubMed ID: 17643772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
    Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C
    Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes.
    Bose A; Munshi R; Tripathy RM; Madhusudana SN; Harish BR; Thaker S; Mahendra BJ; Gunale B; Gogtay NJ; Thatte UM; Mani RS; Manjunath K; George K; Yajaman AB; Sahai A; Dhere RM; Alex RG; Adhikari DD; Abhilash ; Raghava V; Kumbhar D; Behera TR; Kulkarni PS
    Vaccine; 2016 Sep; 34(40):4820-6. PubMed ID: 27554534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.
    Pineda-Peña AC; Jiang Q; Petit C; Korejwo-Peyramond J; Donazzolo Y; Latreille M; Homery MC; Babin V; Benamor S; Pichon S; Guinet-Morlot F; Minutello AM
    Clin Infect Dis; 2024 Jun; 78(6):1748-1756. PubMed ID: 38478634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.